Auranofin
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Auranofin
- Pharmacist Assessment Report
- Auranofin: gold(I) compound, anti-inflammatory agent → colobomatous microphthalmia-rhizomelic dysplasia syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Auranofin: gold(I) compound, anti-inflammatory agent → colobomatous microphthalmia-rhizomelic dysplasia syndrome
One-Sentence Summary
Auranofin is an oral gold(I) compound marketed in Australia. The TxGNN model predicts it may be relevant to colobomatous microphthalmia-rhizomelic dysplasia syndrome, with a score of 0.9956. There are currently no clinical trials and no publications supporting this prediction, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 0.9956 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Auranofin is generally described in the wider literature as a gold(I) compound that inhibits thioredoxin reductase and modulates redox signalling and inflammation. These details should be verified from primary sources.
No mechanistic link between these pathways and the biology of this ultra-rare developmental syndrome can be established from the data compiled for this report. Any such link would be speculative. The high TxGNN score is a computational prediction only, and it may reflect network proximity or sparse annotation of rare diseases rather than true biological relevance.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1095P | Ridaura | Tablet 3 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 86 potential interactions were identified in total. Examples of those rated Major include:
- Deferiprone
- Proguanil
- Chloroquine
Moderate-rated examples include metronidazole, rosuvastatin, simvastatin, tinidazole, benznidazole and disulfiram. Other listed interactions (e.g. warfarin, prednisone, prednisolone and proton pump inhibitors) have an unclassified severity.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No clinical trials or publications address this syndrome, and no mechanistic link can be established from the available data (evidence level L5).
To proceed, the following is needed:
- Verified mechanism of action data for auranofin from primary sources
- Evidence of a plausible biological link between auranofin’s pathways and the pathophysiology of this syndrome
- Preclinical or clinical studies directly addressing this disease
- Review of the TGA Product Information for warnings and contraindications, particularly the major drug interactions listed above
- Assessment of whether oral administration is suitable for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.